Chronic Lymphocytic Leukemia Patient Clustering Based on Somatic Hypermutation (SHM) Analysis

2017 ◽  
pp. 127-138 ◽  
Author(s):  
Eleftheria Polychronidou ◽  
Aliki Xochelli ◽  
Panagiotis Moschonas ◽  
Stavros Papadopoulos ◽  
Anastasia Hatzidimitriou ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Somatic Hypermutation ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient

Infected herpes zoster in a chronic lymphocytic leukemia patient treated with ibrutinib

2019 ◽  
Vol 85 ◽  
pp. S40 ◽  
Author(s):  
M. Okay ◽  
Y. Buyukasik ◽  
S. Aksu ◽  
I. Haznedaroglu ◽  
N. Sayinalp
Keyword(s):  
Herpes Zoster ◽  
Chronic Lymphocytic Leukemia ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient

scholarly journals Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia

2019 ◽  
Vol 7 ◽  
pp. 2050313X1882391 ◽  
Author(s):  
Sharad Khurana ◽  
Salman Ahmed ◽  
Victoria R Alegria ◽  
Sonikpreet Aulakh ◽  
Meghna Ailawadhi ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Partial Remission ◽  
Single Agent ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Viable Option ◽  
Leukemia Patient ◽  
Therapeutic Landscape ◽  
Response Status ◽  
Anti Cd20

Obinutuzumab is used for the treatment of chronic lymphocytic leukemia. So far there are no data of using this for retreatment in patients who have received it previously. We introduced obinutuzumab for the retreatment in a chronic lymphocytic leukemia patient, who had first achieved partial remission with it and eventually relapsed over a course of 2.5 years. After retreatment with single-agent obinutuzumab, the patient achieved a partial remission again within one cycle and continues to maintain the response status. This case is a platform for considering obinutuzumab as a viable option for retreatment of chronic lymphocytic leukemia patients who have received it before, similar to the pattern of use for other anti-CD20 monoclonal antibodies in this disease, including rituximab.

Expression of a receptor for sheep erythrocytes by B lymphocytes from a chronic lymphocytic leukemia patient

1983 ◽  
Vol 27 (2) ◽  
pp. 210-222 ◽  
Author(s):  
Roberto Sitia ◽  
Luca Sciariada ◽  
Antonio Zicca ◽  
Arnaldo Leprini ◽  
Riccardo Ghio ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Lymphocytes ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Sheep Erythrocytes ◽  
Leukemia Patient

Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient

2008 ◽  
Vol 32 (2) ◽  
pp. 363-365 ◽  
Author(s):  
Pasquale Niscola ◽  
Maria Ilaria Del Principe ◽  
Massimiliano Palombi ◽  
Stefano Fratoni ◽  
Daniela Piccioni ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient ◽  
Cell Chronic Lymphocytic Leukemia

Central Nervous System Expression of a Monoclonal Paraprotein in a Chronic Lymphocytic Leukemia Patient

1992 ◽  
Vol 88 (1) ◽  
pp. 37-40 ◽  
Author(s):  
Phillip Ruiz ◽  
Manijeh Moezzi ◽  
Wilfredo Chamizo ◽  
Parvin Ganjei ◽  
Clarence C. Whitcomb ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Chronic Lymphocytic Leukemia ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient

Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod

2005 ◽  
Vol 46 (6) ◽  
pp. 935-939 ◽  
Author(s):  
David E Spaner ◽  
Richard L Miller ◽  
Jenny Mena ◽  
Larry Grossman ◽  
Vicki Sorrenti ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Toll Like Receptor ◽  
Leukemia Patient
Sign in / Sign up

Export Citation Format

Share Document